Novartis Ag · SIX:NOVN
Novartis — Q2 2025 Earnings Presentation
79 slides from Novartis's earnings presentation, Jul 17, 2025
Slide 1: Q2 2025 Results Investor presentation
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q2 2025 Results Q2 2025 Results Investorpresentation Investor presentation July17, July 17, 2025 2025 Novartis Q2 Results | July 17, 2025 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potenti
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Company overview Company overview Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q2 Results | July 17, 2025 3
Slide 4: Double-digit sales growth and core margin expansion in Q2, upgraded FY 2025 guidance
Content Click below to navigate Novartis delivered double-digit sales growth and core margin expansion in Q2, supporting an upgrade to FY 2025 bottom-line guidance through the document Company overview Financial review Conclusions Sales Core1 operating income Innovation highlights USD bn, % cc1 USD
Slide 5: Priority brands continued to drive robust growth
GROWTH Content Click below to navigate Priority brands continued to drive robust growth, demonstrating the replacement power in our portfolio through the document Company overview Financial review Q2 sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million cc Appendix 1,177 460 64
Slide 6: Kisqali grew +64% cc in Q2
GROWTH Content Click below to navigate Kisqali® grew +64% cc in Q2, achieving TRx leadership in mBC and building momentum in eBC through the document Company overview Financial review Sales evolution US Total Brand NBRx (R3M)1 US: +100% in Q2 Conclusions USD m, % cc • mBC leadership in both NBRx (50
Slide 7: Kesimpta grew +33% cc in Q2
GROWTH Content Click below to navigate Kesimpta® grew +33% cc in Q2, fueled by continued strong demand growth through the document Company overview Financial review Sales evolution US: +28% in Q2 Conclusions USD m, % cc • Continued TRx growth +23% vs. PY, gaining +2.3pts market share1 US Ex-US • Acc
Slide 8: Pluvicto grew +30% cc in Q2
GROWTH Content Click below to navigate Pluvicto® grew +30% cc in Q2, with promising uptake since pre-taxane indication approval in US through the document Company overview ® Financial review Sales evolution US pre-taxane launch off to a strong start Conclusions USD m, % cc • Significant QoQ growth i
Slide 9: Positive Phase III PSMAddition study for Pluvicto in mHSPC
INNOVATION Content Click below to navigate Positive Phase 3 PSMAddition study for Pluvicto® paves the way for potential further expansion in mHSPC through the document Company overview ® Financial review Primary endpoint met Study design1 Conclusions • Statistically significant and clinically meanin
Slide 10: Leqvio grew +61% cc in Q2
GROWTH Content Click below to navigate Leqvio® grew +61% cc in Q2, on track for blockbuster status in 2025 through the document Company overview Financial review Sales evolution US: +47%, outpacing advanced lipid-lowering market1,2 Conclusions USD m, % cc • MOTRx +56% vs. PY (market +35%) US Ex-US •
Slide 11: Scemblix grew +79% cc in Q2
GROWTH Content Click below to navigate Scemblix® grew +79% cc in Q2, on track for blockbuster status in 2025 with strong momentum in early lines and global leadership in 3L+ CML through the document Company overview Financial review Sales evolution US All LoT NBRx Share (R3M)1 US: Achieved NBRx lead
Slide 12: Cosentyx growth moderated to +6% cc in Q2
GROWTH Content Click below to navigate Cosentyx® growth moderated to +6% cc in Q2; expect mid-single digit growth in FY 2025 through the document Company overview Financial review Sales evolution Continued solid demand for launches in US (HS, IV) Conclusions USD m, % cc • HS: Continuing to grow the
Slide 13: Entresto grew +22% cc in Q2
GROWTH Content Click below to navigate Entresto® grew +22% cc in Q2, as consistent performance continued through the document Company overview Financial review Sales evolution Fully met Entresto® US mid-2025 Expect continued growth ex-US Conclusions USD m, % growth financial planning assumption • St
Slide 14: Renal portfolio continues to advance
GROWTH Content Click below to navigate Renal portfolio continues to advance with multiple ongoing launches and new long-term data for zigakibart through the document Company overview Financial review Fabhalta Vanrafia2 Conclusions IgAN growing steadily in US, with continued high persistency Strong H
Slide 15: Remibrutinib Phase II food allergy study
GROWTH Content Click below to navigate Remibrutinib demonstrated a clinically meaningful and statistically significant benefit in Phase II food allergy study through the document Company overview Financial review Primary endpoint met Study design Conclusions • Primary endpoint: Tolerating ≥ 600 mg o
Slide 16: YTB323 interim Phase I/II data in severe refractory SLE
GROWTH Content Click below to navigate YTB3231: Interim Phase I/II data2 indicate sustained clinical improvement in severe refractory Systemic Lupus Erythematosus (SLE) through the document Company overview Financial review SLEDAI-2K total score over time, mean (SE)3 Distribution of SLEDAI−2K items4
Slide 17: Broad development program for YTB323 in autoimmune diseases
GROWTH Content Click below to navigate Advancing a broad development program for YTB323 in autoimmune diseases, including four pivotal studies through the document Company overview Financial review Rheumatology Selected projects (indication) Pre-clinical Phase I/II Phase II Phase III Conclusions srS
Slide 18: Key innovation milestones in 2025
INNOVATION Content Click below to navigate Key innovation milestones in 2025 through the document Company overview 2025 selected key events (expected) H1 2025 H2 2025 Status as of end Q2 Financial review Regulatory Atrasentan IgAN US US approval (Q2) Fabhalta® (iptacopan) C3G US, JP EU US, EU approv
Slide 19: Financial review and 2025 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Financial review Financial review References and 2025 guidance and 2025 guidance Harry Kirsch Chief Financial Officer Harry Kirsch Chief Financial Officer Novartis Q2 Results | July 17, 2025 1
Slide 20: Q2 net sales grew +11% cc with strong core margin expansion
FINANCIAL PROFILE Content Click below to navigate Q2 net sales grew +11% cc1, with strong core1 margin expansion through the document Company overview Financial review Key figures1 Q2 Q2 Change vs. PY H1 H1 Change vs. PY Conclusions USD million 2024 2025 % USD % cc 2024 2025 % USD % cc Appendix Tota
Slide 21: Continued focus on Free Cash Flow generation
FINANCIAL PROFILE Content Click below to navigate Continued focus on Free Cash Flow generation through the document Company overview Financial review Free Cash Flow1 Conclusions USD billion Appendix 2025 growth driven +46% References by higher core operating income 9.7 6.7 H1 2024 H1 2025 1. Free Ca
Slide 22: Shareholder-friendly capital allocation, new up-to USD 10bn share buyback
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy, initiating a new up-to USD 10bn share buyback through the document Company overview Financial review Conclusions Investing in the business Returning capital to shareholders Appendix Inv
Slide 23: Raising Novartis 2025 full year core operating income guidance
FINANCIAL PROFILE Content Click below to navigate Raising Novartis 2025 full year core1 operating income guidance through the document Expected, barring unforeseen events; growth vs. PY in cc1 Company overview Financial review Conclusions Net sales Core operating income Appendix expected to grow exp
Slide 24: Underlying growth trends expected throughout 2025
FINANCIAL PROFILE Content Click below to navigate Strong underlying growth trends expected throughout 2025, with Q4 impacted by prior-year one-timers and potential US generics impact1 through the document Company overview Financial review 2025 growth vs. PY (cc2) Actual Simulation Conclusions Illust
Slide 25: Expected currency impact for full year 2025
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for full year 2025 through the document Company overview Financial review Currency impact vs. PY Conclusions %pts, assuming mid-July exchange rates prevail in 2025 Appendix FX impact on Net sales FX impact on Core operating i
Slide 26: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q2 Results | July 17, 2025 26
Slide 27: Novartis delivered a strong Q2
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Novartis delivered Key launches are Continued to Upgraded FY 2025 a strong Q2, with accelerating with advance our bottom-line double-digit sales consistent strong pipeline, reaching guidance a
Slide 28: Thank you to Harry Kirsch and welcome to Mukul Mehta
Content Click below to navigate Thank you to Harry for his unwavering commitment and over 22 years at Novartis, and a warm welcome to Mukul to his new role effective March 2026 through the document Company overview Financial review Conclusions Appendix References Harry Kirsch Mukul Mehta Retiring an
Slide 29: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Appendix References Novartis Q2 Results | July 17, 2025 29
Slide 30: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase I/II Phase III Registration Total Conclusions Oncology 24 10 0 34 Appendix Solid tumors 20 5 0 25 Innovation: Pipeline overview Hematology 4 5 0 9 Financial perfo
Slide 31: Novartis pipeline in Phase I lead indications
INNOVATION Content Click below to navigate Novartis pipeline in Phase I 17 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis Solid tumors Financi
Slide 32: Novartis pipeline in Phase II lead indications
INNOVATION Content Click below to navigate Novartis pipeline in Phase II 19 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFV890 DFV890 NLRP3 inhibitor Osteoarthritis Solid tumors Financi
Slide 33: Novartis pipeline in Phase III lead indications
INNOVATION Content Click below to navigate Novartis pipeline in Phase III 6 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, p
Slide 34: Novartis pipeline in registration lead indication
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indication through the document Company overview Others Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) LOU064 remibrutinib BTK inhibitor Chronic spontaneous urticaria Financial review
Slide 35: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate Novartis submission schedule through the document New Molecular Entities: Lead and supplementary indications Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions remibrutinib ianalumab a
Slide 36: Novartis submission schedule: existing brands
INNOVATION Content Click below to navigate Novartis submission schedule through the document Supplementary indications for existing brands Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions Leqvio® Cosentyx® Fabhalta® Fabhalta®
Slide 37: Net debt increased by USD 7.7bn
FINANCIAL PROFILE Content Click below to navigate Net debt1 increased by USD 7.7bn as strong FCF2 was more than offset by mainly the annual dividend and share buybacks through the document Company overview Financial review USD bn Conclusions -7.7 Appendix Innovation: Pipeline overview Financial perf
Slide 38: Clinical Trials Update
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience IR Clinical Includes
Slide 39: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Cardiovascular, Innovation: Pipeline overview Financial performance Cardiovascular, Innovation: Clinical trials Renal and Metabolic > C ardiovascular, Renal and Metabolic > I mmunology > N eur
Slide 40: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 41: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 42: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 43: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 44: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) Financial review Indication CVRR (Primary prevention) Phase Phase 3 Conclusions Patients 14000 Primary Time to the first occurrence of 4P-MACE Appendix
Slide 45: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 46: QCZ484
Content Click below to navigate QCZ484 through the document Company overview NCT06857955 (CQCZ484A12201) Financial review Indication Hypertension Phase Phase 2 Conclusions Patients 380 Primary Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by Appendix Outcome ambulatory b
Slide 47: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 350 Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months ] Appendi
Slide 48: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience Immunology > O ncology > I n-mar
Slide 49: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 50: GHZ339
Content Click below to navigate GHZ339 through the document Company overview NCT06947993 (CADPT17A12201) Financial review Indication Atopic dermatitis Phase Phase 2 Conclusions Patients 224 Primary Outcome Change from baseline in the Eczema Area and Severity Index (EASI) score at Week Appendix Measu
Slide 51: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 52: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögre
Slide 53: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 54: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT06470048 (CVAY736S12201) Financial review Indication Systemic sclerosis Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in Systemic
Slide 55: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 56: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT06799000 RECHARGE1 (CLOU064J12301) NCT06840392 RECHARGE2 (CLOU064J12302) Financial review Indication Hidradenitis suppurativa Indication Hidradenitis suppurativa Phase P
Slide 57: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience Neuroscience > O ncology > I n
Slide 58: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor through the document Company overview NCT123456 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 Appendix in Myasthenia Gravis Ac
Slide 59: Kesimpta - anti-CD20
Content Click below to navigate Kesimpta® - anti-CD20 through the document Company overview NCT06869785 FILIOS (COMB157Q12301) Financial review Indication Multiple sclerosis new dosing regimen Phase Phase 3 Conclusions Patients 180 Primary Ofatumumab plasma pharmacokinetics - area under the curve, u
Slide 60: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 61: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 62: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT06744920 RELIEVE (CLOU064O12301) Financial review Indication Myasthenia Gravis Phase Phase 3 Conclusions Patients 180 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily L
Slide 63: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience Oncology > O ncology > I n-market
Slide 64: 225Ac-PSMA-617 - Radioligand therapy target PSMA
Content Click below to navigate 225Ac-PSMA-617 - Radioligand therapy target PSMA through the document Company overview NCT06780670 AcTFirst (CAAA817B12301) Financial review Indication Metastatic castration-resistant prostate cancer Phase Phase 3 Conclusions Patients 605 Primary Radiographic Progress
Slide 65: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune
Slide 66: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 67: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 75 Primary Percentage of participants with complete TMA response wi
Slide 68: Lutathera - Radioligand therapy target SSTR
Content Click below to navigate Lutathera® - Radioligand therapy target SSTR through the document Company overview NCT06784752 NETTER-3 (CAAA601A62301) Financial review Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Conclusions Patients 240 Primary Progression Free Survival (P
Slide 69: luxdegalutamide - Androgen receptor protein degrader
Content Click below to navigate luxdegalutamide - Androgen receptor protein degrader through the document Company overview NCT07047118 (CJSB462B12201) NCT06991556 (CJSB462C12201) Financial review Indication Metastatic castration resistant prostate cancer Indication Metastatic hormonal sensitive pros
Slide 70: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic hormone sensitive prostate cancer Phase Phase 3 Conclusions Patients 1126 Primary Radiographic Progression
Slide 71: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 72: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix In-market Brands Innovation: Pipeline overview Financial performance In-market Brands Innovation: Clinical trials & Global Health > C ardiovascular, Renal and Metabolic > I mmunology > N euros
Slide 73: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 74: ganaplacide/lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1720 Primary PCR-corrected adequa
Slide 75: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 76: Abbreviations
Content Click below to navigate Abbreviations through the document Abbreviation Full Form Abbreviation Full Form Company overview AAV Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis LoE Loss of Exclusivity ACC American College of Cardiology mBC Metastatic Breast Cancer Financial re
Slide 77: References 1 of 3
Content Click below to navigate References 1 of 3 through the document Company overview Kisqali® (slide 6 references) Financial review 1 IQVIA Market Sizing Monthly Report, May 2025; Data lag: ~ 2 months. 2 Of CDK4/6 market, US rolling 3 months ending May 2025, IQVIA Breast Cancer Market Sizing repo
Slide 78: References 2 of 3
Content Click below to navigate References 2 of 3 through the document Company overview Leqvio® (slide 10 references) Financial review 1 Includes PCSK9 monoclonal antibodies and bempedoic acid. 2 MOTRx Q2 QTD ending 20-Jun-2025 vs. PY. Conclusions 3 800+ Priority Health Systems, depth growth Q2 2025
Slide 79: References 3 of 3
Content Click below to navigate References 3 of 3 through the document Company overview Renal portfolio (slide 14 references) Financial review 1 Fabhalta prescribed patients. There is no data on the impact of Fabhalta on glomerular inflammation. 2 Approved by FDA in Apr 2025. All information specifi